rhHsc70 is not a therapeutic viability in preserving neuromuscular junction innervation in the SOD1 mouse model of ALS

The Mulligan Lab at Wake Forest University was working on a dose response study of the Hsp70 protein with the hopes that their ALS scientists and clinicians would be able to start to design initial clinical trials in patients. Unexpectedly, the protein does not prevent neuromuscular junction denervation in the mouse model of ALS.